Egis Gyogyszergyar Zrt.

Xamarin Inc.

Virostatics Srl

Microsoft Technology Licensing, LLC

Chinoin Gyogyszer Es Vegyeszeti Termekek Gyara Rt.

Egis Gyogyszergyar Nyilvanosan Mukodo Reszvenytarsasag

Abb K-flow Inc.

Vichem Chemie Kutató Kft.

Onp Holdings Se

Euroapi Hungary Limited Liability Company

Zoltán Varga

György Kéri

Miguel De Icaza

Zoltán Greff

László Szlávik

Gábor Németh

Rolf Bjarne Kvinge

Sebastien Pouliot

Rodrigo Kumpera

Aaron Dean Bockover

Gyula Simig

Balazs Volk

László Örfi

Balázs Volk

Franco Lori

Adrienn Keszthelyi

Antonio Solinas

Andras Dancso

Bálint Nyulasi

Gábor Berecz

Mátyás Milen

András Mravik

Davide De Forni

Beatrix Bali

Daniel Ulej

James Chafouleas

Zsuzsanna Kardos

Irén Hortobágyi

István Lászlófi

Kálmán Nagy

Laszlo Pongo

Istvan Ling

Gyula Lukacs

Wayne Pratt

Endre Mikulásik

Martin Kane

Gyula Lukács

Imre Juhász

Maria Tothne Lauritz

Gyorgyi Kovanyine Lax

Jozsef Alesz

Tamás Spaits

Tamás Gregor

Eva Szabo

Attila Virág

Zoltan Biro

Imre Markovits

Krisztina Fodorné Kocsmár

Imre Kapui

György Clementis

Imola Ritz

Jeno Peter Seres

László Õrfi

Ede Laszlo Marvanyos

Csaba Szántai Kis

Livia Gregorné Boros

Tamás Mórász

Máté Hudák

Balazs Peregi

Gyöngyi Heréb

Réka Eszter Puskás

Gábor Attila Bacher

Beatrix Bánkövi

Gitta Kiss

Ottó Albrecht

Gyorgy Jeges

Peter Gregor

László Orfi

Endre MIKULÁSIK

Method for the production of formula (I) lumateperone or its acid addition salts so that the enantiomer compound with stereochemistry 6bR,10aS is separated form the cis racemate using resolution and the formula (II) stereoisomer is alkylated with 4-halo-4'-fluoro butyrophenone (X=I, Br, Cl) to produce the formula (I) lumateperone, or optionally its acid addition salt. The object of the invention also relates to the amorphous form of the morphologically uniform p-toluenesulfonic acid salt of lumateperone and to the naphthalene-2-sulfonic acid salt of lumateperone, to the 1:2 stoichiometry salt of lumateperone formed with naphthalene-2-sulfonic acid.

Method for the production of lumateperone and its salts

The invention relates to a robust and reproducible process for the preparation of polymorph form B of treprostinil diethanolamine salt, comprising the following steps: a. treprostinil is dissolved in methanol, b. to the solution of step a) diethanolamine or its methanol solution is added, c. the reaction mixture of step b) is agitated till dissolution, d. when salt formation is completed in step c), first portion of an aprotic solvent is added to the solution, e. the solution of step d) is filtered to remove insoluble impurities, f. the filtrate of step e) is seeded with polymorph form B of treprostinil diethanolamine salt, g. to the crystal suspension obtained in step f) a second portion of the aprotic solvent is added, h. the suspension of step g) is agitated until crystallisation is completed, i. the crystals are separated, washed and dried.

Process for the preparation of polymorph form B of treprostinil diethanolamine salt

Novel 4,6-disubstituted aminopyrimidine derivatives with the following structure (I) have anti-HIV activity.

4,6-disubstituted aminopyrimidine derivatives have anti-HIV activity

Embodiments are directed towards generating applications that include multi-sized types running in managed code. During the compilation of an intermediate language version of an application, if a multi-size type is encountered, a runtime engine may perform actions to process the multi-size types. Accordingly, architecture information associated with the target computer may be determined. Data types corresponding to the architecture of the target computer and the multi-sized types may be determined based on the architecture information. Native code calls associated with an intermediate language code calls may be determined such that the parameters of the native code calls match the architecture dependent data types. And, a machine code version of the intermediate language code call may be generated. The generated machine code version of the intermediate language code may be executed with the data types specific to the target computer.

Multi-sized data types for managed code

The invention relates to normal or acidic salts of dasatinib and the hydrate and solvate forms thereof. More specifically the invention concerns: dasatinib cyclamic acid salt, dasatinib cyclamic acid (1:1) salt Form I, dasatinib cyclamic acid (1:1) salt Form II, dasatinib hydrogen bromide (1:2) salt, dasatinib methane sulfonic acid (1:2) salt, dasatinib p-toluenesulfonic acid (1:1) dihydrate salt, anhydrous dasatinib p-toluenesulfonic acid (1:1) salt Form I, anhydrous dasatinib p-toluenesulfonic acid (1:1) salt Form II, dasatinib p-toluenesulfonic acid (1:1) salt methanol solvate. Moreover the invention relates process for preparing dasatinib salts, pharmaceutical compositions comprising thereof and the use of dasatinib salts the treatment of cancer.

Dasatinib salts

The invention relates to an improved process for the preparation of pharmaceutical active ingredients and also to high purity salts and pharmaceutical compositions prepared by said process. More particularly the invention relates to an economical process for the preparation of the compound having the international non-proprietary name (INN) vortioxetine and the chemical nomenclature 1-[2-(2,4-dimethyl-phenylsulfanyl)-phenyl]-piperazine. Vortioxetine corresponds to the following Formula  Still more particularly the invention relates to the preparation of high purity vortioxetine L-(+)-mandelate salt of the Formula IX, the conversion of this salt into other highly pure salts and also to the formulation of said salts.

Process for the preparation of vortioxetine salts

The invention relates compounds of general formula (I) and pharmaceutically acceptable salts and solvates thereof wherein Furthermore, the present invention is directed to pharmaceutical composition containing at least one compound of general formula (I) and/or pharmaceutically acceptable salts or solvates thereof and for the use of them for the preparation of pharmaceutical compositions for the prophylaxis and/or the treatment of protein kinase related, especially CDK9-related diseases e.g. cell proliferative disease, infectious disease, pain, cardiovascular disease and inflammation.

4-phenylamino-pyrimidine derivatives having protein kinase inhibitor activity

A method for purifying diatomaceous earth, whose natural colloidal structure is retained, which includes preparing a suspension of diatomaceous earth in a liquid wherein diatomaceous earth is insoluble, separating diatomaceous earth from the suspension, treating diatomaceous earth with an inorganic or organic acid, heat-treating the thus obtained product at a temperature not higher than 300&#xb0; C., subjecting the product obtained to oxidative treatment and drying the purified product.

Method for purifying diatomaceous earth

Apparatus for measuring the mass flow of a fluid within a defined fluid stream including a conduit having two substantially parallel, flexible and continuous flow tubes fixedly mounted at their ends to a centrally positioned housing forming a flow splitter and a flow converger for directing the flow from the inlet and for directing the flow into the outlet between the apparatus and the fluid stream. The ends of each flow tube positioned proximal to one another and to the center of gravity formed by the shape of the flow tube. Each flow tube substantially forming a 'B' shape having a first loop, a connecting portion and a second loop. The first and second loops being symmetrical with respect to the connecting portion and extending laterally from the center of gravity at a greater distance than the displacement of the connecting portion to the center of gravity. The flow tubes being oscillated in opposing modes at the connecting portion so as to produce a measurable Coriolis reaction force by the fluid on the flow tubes. The vibration means being capable of selectively oscillating the flow tube at least one discrete resonant frequency higher than the fundamental resonance of the flow tube so as to create waves along the tube length and form nodal points which are substantially stationary with respect to the vibrating flow tube.

Mass flow measuring device

Growing community of inventors

Budapest, Hungary

Zoltán Varga